The Cutting Edge
August 1999

Treatment of Granuloma Faciale With the 585-nm Pulsed Dye Laser

Author Affiliations



Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Dermatol. 1999;135(8):903-905. doi:10.1001/archderm.135.8.903

A 41-year-old white man with a long history of acne rosacea was referred for evaluation of a persistent erythematous lesion on his nose. The lesion had been present for 2 years and had proved resistant to topical and oral antibiotic therapy. Examination of the patient's face revealed malar erythema, scattered acneiform papules, and an absence of comedones, consistent with mild acne rosacea. On the dorsum of the nose, there was a discrete 2-cm, reddish-brown, indurated plaque with prominent telangiectasias (Figure 1). The clinical differential diagnosis included granuloma faciale, sarcoidosis, and discoid lupus erythematosus. Histopathologic findings were consistent with granuloma faciale and revealed a mixed infiltrate in the papillary and reticular dermis composed of neutrophils, eosinophils, plasma cells, lymphocytes, and monocytes. There was an overlying Grenz zone noted, as well as associated leukocytoclastic vasculitis.

Figure 1.
Image not available

Pretreatment appearance of granuloma faciale on the dorsum of the nose.


Granuloma faciale is a benign granulomatous process that is frequently resistant to therapy. Multiple medical and surgical modalities have been suggested, but none have been consistently efficacious. The prominent facial location of this lesion required that the posttreatment residual be cosmetically acceptable as well. Our challenge was to treat this patient's persistent and disfiguring lesion effectively, yet minimize the risk for scarring, dyspigmentation, or systemic adverse effects.


The 585-nm pulsed dye laser is the treatment of choice for a variety of vascular lesions.1 It uses the concept of selective photothermolysis to target the oxyhemoglobin within blood vessels, while minimizing collateral damage. The reddish-brown color and prominent telangiectasias of granuloma faciale suggested that it might be amenable to treatment with this laser.

The lesion underwent 2 treatments, spaced 2 months apart, with a flashlamp-pumped pulsed dye laser (SPTL-1b; Candela Laser Corp, Wayland, Mass). A wavelength emission of 585 nm and a pulse duration of 450 microseconds were used. The treatments were performed with 5 mm minimally overlapping spots at 8.0 J/cm2 for the first treatment and 8.5 J/cm2 for the second treatment. No anesthesia was needed and there was no significant postoperative discomfort. Follow-up 2 months after the second pulsed dye laser treatment (Figure 2) and at 6 years (Figure 3) confirmed clinical eradication of the lesion without scarring or pigmentary change.

Figure 2.
Image not available

Clinical resolution 2 months after the second 585-nm pulsed dye laser treatment.

Figure 3.
Image not available

No clinical recurrence of granuloma faciale at 6-year follow-up. Note interim progression of underlying rhinophyma.


The term granuloma faciale was first coined by Pinkus2 in 1952. Formerly, this rare cutaneous disorder had been called eosinophilic granuloma of the skin. While granuloma faciale has been reported in children and adult women,3 the typical patient is a middle-aged white man. Clinically, granuloma faciale presents as a reddish-brown or violaceous plaque on the face, often with follicular accentuation and superficial telangiectasias. The sites of predilection are the sides (30%) and tip (7%) of the nose, preauricular area (22%), cheeks (22%), forehead (15%), tip of the nose (7%), and helix of the ear (4%).4 Extrafacial granuloma faciale has also been reported but is rare.5,6 The clinical differential diagnosis includes sarcoidosis, discoid lupus erythematosus, lymphocytic infiltrate of Jessner, polymorphous light eruption, rosacea, lymphoma cuffs, histiocytosis X, erythema elevatum diutinum, infectious granuloma, and basal cell carcinoma.710 Histologically, granuloma faciale displays a dense polymorphous infiltrate of the upper two thirds of the dermis. Eosinophils may be present but are not essential for diagnosis. There is sparing of the epidermis, with a notable Grenz zone and a leukocytoclastic vasculitis in the upper dermis.11

Response to therapy is variable. Medical modalities that have been proposed include colchicine,12 dapsone,1316 antimalarials,7,17 gold injections,4 isoniazid,4,12 clofazimine,18,19 topical psoralen with UV-A,20 and corticosteroids in topical,14,17 intralesional,3,7,17,21 and systemic forms.4,7,12 None of them have been consistently effective, and a large proportion of them have substantial well-known adverse effects, such as hemorrhagic gastroenteritis, blood dyscrasias, oculotoxicity, nephrotoxicity, peripheral neuropathy, skin discoloration, actinic damage, atrophy, and adrenal suppression.22 Surgical treatments have included wide excision,2,20 cryotherapy,2325 radiation,4,7,21 electrodesiccation with and without curettage,4 and dermabrasion.4,26 These modalities have been used with varying degrees of success, and all pose a significant risk for permanent pigmentary changes and scarring.

One of the first lasers used to treat granuloma faciale was the carbon dioxide laser. This infrared laser vaporizes tissues in a nonselective manner and has the associated risks of hypopigmentation and scarring. Wheeland et al27 reported the successful treatment of granuloma faciale with this laser. Other investigators, however, were unable to reproduce their results. In a side-by-side comparison of electrosurgery, carbon dioxide laser, and dermabrasion, Dinehart et al28 noted a recurrence in all 3 sites at 1 year. Also, the argon laser was thought to be a promising treatment for granuloma faciale. Apfelberg et al12 reported total and complete resolution of granuloma faciale with the argon laser, but their treatment was complicated by a white collagenous scar.

The pulsed dye laser, with a wavelength of 585 nm and a pulse duration of 450 microseconds, is highly effective for the selective destruction of vascular lesions, especially pediatric port-wine stains,29,30 superficial hemangiomas,30 and telangiectasias.31 Its unsurpassed safety profile and efficacy are attributable to its ability to achieve selective photothermolysis.3234 The 585-nm pulsed dye laser emits energy that is strongly absorbed by oxyhemoglobin, and its 450-microsecond pulse duration is shorter than the 1- to 5-microsecond thermal relaxation time of blood vessels 50 to 100 µm in diameter.35

In the case presented herein, the lesion had a distinct reddish-brown hue and prominent telangiectasias, which suggested that it might respond to the 585-nm pulsed dye laser. The result was persistent clinical eradication of the lesion without evidence of scarring or pigment change at the 6-year follow-up. Since the time that our patient was treated, the short-pulsed or scanned carbon dioxide and erbium:YAG lasers for skin resurfacing have been added to the surgeon's armamentarium. It is our belief that these lasers, with their precise depth control, may also provide safe and effective treatment options for granuloma faciale. Further studies will be needed to confirm this.

In summary, we report a case of granuloma faciale on the nose of a white man that was successfully treated by the 585-nm pulsed dye laser. Because of the noninvasive nature of this laser, there was minimal postoperative discomfort and no complicated wound care. Persistent clinical eradication for 6 years was achieved without scarring, permanent pigmentary alteration, or systemic morbidity. The 585-nm pulsed dye laser provided safe and effective treatment for this often-resistant lesion and warrants further investigation on a larger scale.

Ross  BSLevine  V JAshinoff  R Laser treatment of acquired vascular lesions. Dermatol Clin. 1997;15385- 396Article
Pinkus  H Granuloma faciale. Dermatologica. 1952;105- 8599
Pedace  FJPerry  HO Granuloma faciale: a clinical and histopathologic review. Arch Dermatol. 1966;94387- 396Article
Johnson  WCHigdon  RSHelwig  EB Granuloma faciale. Arch Dermatol. 1959;7942- 52Article
Sears  JKGitter  DGStone  MS Extrafacial granuloma faciale. Arch Dermatol. 1991;127742- 743Article
Rusin  L JDubin  HVTaylor  WB Disseminated granuloma faciale. Arch Dermatol. 1976;1211575- 1577Article
Black  Cl Granuloma faciale. Cutis. 1977;2066- 68
Horn  T Long-standing erythematous facial plaques: granuloma faciale. Arch Dermatol. 1985;1211553- 15541556- 1557Article
Phillips  DKHymes  SR Recurrent facial plaques following full-thickness grafting: granuloma faciale. Arch Dermatol. 1992;1301433- 14341436- 1437Article
Kolbusz  RVPearson  RW Solitary plaque on the cheek: granuloma faciale. Arch Dermatol. 1993;129634- 635637Article
Mehregan  AHashimoto  KMehregan  D Pinkus' Guide to Dermatohistopathology. 6th ed. East Norwalk, Conn Appleton & Lange1995;239- 240
Apfelberg  DBDruker  DMaser  MLash  HSpence  B  JrDeneau  D Granuloma faciale: treatment with the argon laser. Arch Dermatol. 1983;119573- 576Article
Anderson  CR Dapsone in granuloma faciale. Lancet. 1975;1642Article
Goldner  RSina  B Granuloma faciale: the role of dapsone and prior irradiation on the cause of the disease. Cutis. 1984;33478- 480
Guill  MAAton  JK Facial granuloma responsive to dapsone therapy. Arch Dermatol. 1982;118332- 335Article
van de Kerkhof  PCM On the efficacy of dapsone in granuloma faciale. Acta Derm Venereol. 1994;7461- 62
Brown  M Granuloma faciale. Arch Dermatol. 1974;110477- 478Article
Jacyk  WK Facial granuloma in a patient treated with clofazimine. Arch Dermatol. 1981;117597- 598Article
Wollina  UKarte  KGeyer  AStuhlert  ABocker  T Clofazimine in inflammatory facial dermatosis: granuloma faciale and lipogranulomatosis subcutanea (Rothman-Makai). Acta Derm Venereol. 1996;7677- 79
Hudson  LD Granuloma faciale: treatment with topical psoralen and UVA. J Am Acad Dermatol. 1983;8559Article
Arundell  FDBurdick  KH Granuloma faciale treated with intradermal dexamethasone. Arch Dermatol. 1960;82437- 441Article
Wolverton  SEWilkin  JK Systemic Drugs for Skin Diseases.  Philadelphia, Pa WB Saunders Co1991;
Graham  GFStewart  R Cryosurgery for unusual cutaneous neoplasms. J Dermatol Surg Oncol. 1977;3437- 442Article
Franks,  AG Diagnosis: facial granuloma with eosinophils. Arch Dermatol. 1960;821019- 1020
Zacarain  SA Cryosurgery effective for granuloma faciale. J Dermatol Surg Oncol. 1985;1111- 13Article
Bergfeld  WFScholes  HTRoenigk  HH Granuloma faciale: treatment by dermabrasion: report of a case. Clev Clin Q. 1970;37215- 218Article
Wheeland  RGAshley  JRSmith  DEllis  DWheeland  D Carbon dioxide laser treatment of granuloma faciale. J Dermatol Surg Oncol. 1984;10730- 732Article
Dinehart  SMGross  DJDavis  CMHerzberg  AJ Granuloma faciale: comparison of different treatment modalities. Arch Otolaryngol Head Neck Surg. 1990;116849- 851Article
Levine  V JGeronemus  RG Adverse effects associated with the 577 and 585 nanometer pulsed dye laser in the treatment of cutaneous vascular lesions: a study of 500 patients. J Am Acad Dermatol. 1995;32613- 617Article
Garden  JMGeronemus  RG Dermatologic laser surgery. J Dermatol Surg Oncol. 1990;16156- 168Article
Polla  LLTan  OTGarden  JMParrish  JA Tunable pulsed dye laser for the treatment of benign cutaneous vascular ectasia. Dermatologica. 1987;17411- 17Article
Tan  OTSherwood  KGilchrest  BA Treatment of children with port wine stains using the flashlamp-pulsed dye laser. N Engl J Med. 1989;320416- 421Article
Badow  RJWalker  NPJMarkey  AC Treatment of proliferative hemangioma with the 585 nm pulsed dye laser. J Dermatol Surg Oncol. 1996;134700- 704
Geronemus  RG Pulsed dye laser treatment of vascular lesions in children. J Dermatol Surg Oncol. 1993;19303- 309Article
Anderson  RRParrish  JA Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220524- 527Article